Suchergebnisse

With the rapid development of China's tourism industry and the upgrading of residents' consumption structure, competition in the industry has shifted from enterprise-level to supply chain-level. As a result, the tourism supply chain has garnered significant attention. This paper analyzes the tourism industry in the Altay region and concludes that there are still problems with the tourism supply chain, such as unclear departmental management responsibilities, unreasonable resource allocation and maintenance planning, and a lack of cross-scenic area cooperation awareness. From a supply chain perspective, research on the coordination and management of tourism resources in the Altay region of Xinjiang is crucial. This study aims to explore the development of a green tourism supply chain in the Altay region by combining the characteristics and challenges of the tourism industry in the area with successful tourism supply chain cases from both domestic and international sources. The study also aims to propose effective coordination and management strategies for the tourism supply chain in the Altay region to optimize resource utilization. Additionally, suggestions for improving the coordination of the tourism supply chain in the area will be enumerated.

PURPOSE: Clinical trials require significant resources, but benefits are only realized after trial completion and dissemination of results. We comprehensively assessed early discontinuation, registry results reporting, and publication by trial sponsor and subspecialty in urology trials. MATERIALS AND METHODS: We assessed trial registrations from 2007–2019 on ClinicalTrials.gov and publication data from PubMed®/MEDLINE®. Associations between sponsor or subspecialty with early discontinuation were assessed using Cox proportional hazards and results reporting or publication with logistic regression at 3 years after completion. RESULTS: Of 8,636 trials 3,541 (41.0%) were completed and 999 (11.6%) were discontinued. Of completed trials 26.9% reported results and 21.6% were published. Sponsors included academic institutions (53.1%), industry (37.1%) and the U.S. government (9.8%). Academic-sponsored (adjusted HR 0.81, 95% CI 0.69–0.96, p = 0.012) and government-sponsored trials (adjusted HR 0.62, 95% CI 0.49–0.78, p <0.001) were less likely than industry to discontinue early. Government-sponsored trials were more likely to report (adjusted OR 1.72, 95% CI 1.17–2.54, p = 0.006) and publish (adjusted OR 1.89, 95% CI 1.23–2.89, p = 0.004). Academic-sponsored trials were less likely to report (adjusted OR 0.65, CI:0.48–0.88, p = 0.006) but more likely to publish (adjusted OR 1.72, 95% CI 1.25–2.37, p <0.001). These outcomes were similar across subspecialties. However, endourology was more likely to discontinue early (adjusted HR 2.00, 95% CI 1.53–2.95, p <0.001), general urology was more likely to report results (adjusted OR 1.54, 95% CI 1.13–2.11, p = 0.006) and andrology was less likely to publish (adjusted OR 0.53, 95% CI 0.35–0.81, p = 0.003). CONCLUSIONS: Sponsor type is significantly associated with trial completion and dissemination. Government-sponsored trials had the best performance, while industry and academic-sponsored trials lagged in completion and results reporting, respectively. Subspecialty ...